NAN. M. Abdulkhakkimov

N. M. Abdulkhakkimov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


N. M. Abdulkhakkimov has a total of 83 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Results of the ESOSTAT multiple-center prospective study: analysis of 90-day postoperative morbidity and mortality after radical surgery for esophageal and esophagogastric junction cancer

    by A.B. Ryabov, N.M. Abdulkhakimov, V.G. Agadzhanov, M.V. Agasiev, A.E. Anisimov, G.V. Afonin, A.F. Bikmetov, F.P. Vetshev, S.V. Gamayunov, D.V. Erygin, et al.

    Objective. To evaluate 90-day morbidity and mortality rates after elective radical surgery for esophageal and esophagogastric junction cancer within the prospective multiple-center study ESOSTAT. Material and methods. The study included 230 patients from 18 oncology hospitals in the Russian Federation and the Republic of Belarus who underwent elective radical esophagectomy for primary esophageal cancer or esophagogastric junction cancer (Siewert I–II) between March 18 and September 18, 2024. Complications were uniformly recorded using the ESODATA system with severity graded according to the Clavien-Dindo classification. Univariate and multivariate logistic regression analyses were performed to identify risk factors of postoperative complications and mortality. Results. The 90-day mortality rate was 8.7%, in-hospital mortality — 4.8%. The overall complication rate was 41.3%, including surgical complications in 26.5% of patients and redo surgeries in 17.4% of cases. The most common complications were pulmonary (22.1%) and anastomotic leakage (11.3%). The mortality rate associated with anastomotic leakage was 19.2%. Multivariate analysis identified female sex (OR=0.732; 95% CI 0.548–0.978; p=0.035), ECOG status 2 (OR=10.142; 95% CI 1.575–65.366; p=0.015), surgery time (OR=1.003; 95% CI 1.001–1.005; p=0.006), and intraoperative blood loss (OR=1.001; 95% CI 1.000–1.002; p=0.027) as independent predictors of complications. Factors independently associated with 90-day mortality were Charlson comorbidity index >4 (OR=1.260; 95% CI 1.062–1.495; p=0.008), complicated course of esophageal cancer (OR=1.560; 95% CI 0.637–2.305; p=0.025), concomitant pulmonary diseases (OR=3.328; 95% CI 1.083–10.227; p=0.036), and any postoperative complication (OR=36.554; 95% CI 15.800–84.521; p<0.001). Conclusion. The ESOSTAT study is the first in Russia and Belarus to evaluate 90-day morbidity and mortality rates after esophagectomy. Our findings are comparable with international registries, support 90-day follow-up period and identify key prognostic factors. Risk factor analysis will allow patient stratification according to the likelihood of adverse outcomes, facilitate more rigorous patient selection, and ultimately improve safety of surgical treatment.

  • Endoluminal endoscopic surgery in the treatment of patients with early cardioesophageal junction cancer: a comparative analysis with surgical treatment

    by S.A. Sokolov, S.S. Pirogov, A.B. Ryabov, E.D. Fedorov, M.V. Moscalec, A.O. Shveikin, N.M. Abdulkhakimov, D.YU. Kanner

    Objective. To compare the immediate outcomes, long-term oncological outcomes, and quality of life after endoscopic submucosal dissection and surgery in patients with early cardioesophageal cancer (cTis–cT1N0M0, Siewert type II), and to evaluate the possibility of expanding indications for dissection in comorbid patients. Material and methods. A non-randomized multicenter study included 98 patients (endoscopic treatment — 74, surgery — 24). Due to the low radicality of mucosal resection, only the endoscopic submucosal dissection subgroup (n=55) was compared with surgery. After pseudorandomization, two groups of 24 patients each were formed. We analyzed 5-year overall survival, local control, progression-free survival, complications, hospital stay, and quality of life. Results. Endoscopic submucosal dissection compared with surgery (after pseudorandomization, n=24 each): overall survival 87.5% and 90.5% (p=0.7); local control 95.8% and 94.4% (p=0.98); progression-free survival 95.8% and 90.5% (p=0.58); hospital stay 7 and 11 days (p=0.0002); quality of life (total score of the questionnaire, higher — worse) 0.9 and 7 points (p=0.00002). After surgery, quality of life deteriorated (p=0.02), whereas after dissection it did not change (p=0.371). In 13 comorbid patients (Charlson 7—8, ASA III), dissection was performed according to indications expanded relative to standard criteria (comparison with the standard indication group, n=40): tumor size 20 vs 15 mm, p=0.03; cT1b invasion 92.3% vs 17.5%, p=0.00026; poorly differentiated adenocarcinoma 30.8% vs 5%, p=0.016, respectively. Five-year results (expanded indications vs standard): local control 92.3% vs 97.3% (p=0.36), overall survival 59.1% vs 81.2% (p=0.62), progression-free survival 79.4% vs 97.3% (p=0.008), respectively. Conclusion. Endoscopic submucosal dissection for early cardioesophageal junction cancer is non-inferior to surgery in terms of overall survival, local control, and progression-free survival, while providing a shorter hospital stay and better quality of life. Expanding indications is possible in comorbid patients but requires strict dynamic monitoring.

  • Open Access

    Personalized organ-preserving approach to the treatment of early esophagogastric junction cancer: a case repor

    by S. A. Sokolov, S. S. Pirogov, A. B. Ryabov, M. V. Moskalets, A. O Shveikin, V. Yu. Maksimchuk, E. V. Voronina, N. M. Abdulkhakimov, D. Yu. Kanner

    Background. Early esophagogastric junction cancer with submucosal invasion (pT1b) has traditionally been an indication for radical esophagectomy due to the risk of lymphatic metastasis. However, accumulating evidence points to heterogeneity in the biological behavior of these tumors: in patients with a favorable histological profile (low-grade differentiation, absence of lymphovascular and perineural invasion), the rate of metastasis may be comparable to postoperative mortality associated with esophagectomy. A personalized organ‑preserving approach including endoscopic submucosal dissection (ESD) and intraoperative indocyanine green (ICG) navigation of sentinel lymph nodes may potentially avoid debilitating surgery in selected patients. Nevertheless, the safety and efficacy of this strategy for deep submucosal invasion (sm2, depth >500 μm) remain controversial. Case presentation. A 63‑year‑old patient with early esophagogastric junction cancer (cT1aN0M0, Siewert type II ) underwent combined modality treatment including laparoscopic ICG navigation with removal of two sentinel lymph nodes along the lesser curvature of the stomach (frozen‑section analysis showed no metastases) and simultaneous endoscopic submucosal dissection (ESD). Final histopathological examination of the resected specimen revealed a well‑differentiated adenocarcinoma pT1b sm2 (>500 μm) with no lymphovascular or perineural invasion, a negative vertical margin, but scattered tumor cells in the coagulated horizontal margin. Two months later, residual tumor was diagnosed and repeat ESD achieved R0 resection. Seventeen months after the primary procedure, a solitary lymphogenous metastasis was detected along the left gastric artery. Laparoscopic selective lymphadenectomy and adjuvant polychemotherapy (8 cycles of XELOX) were performed. No signs of recurrence were observed 4.5 years after repeat ESD and 3 years after lymphadenectomy. Conclusion. This case report demonstrates that a personalized organ‑preserving approach (ESD with ICG‑guided sentinel lymph node navigation) can be implemented in carefully selected patients with early high‑risk esophagogastric junction cancer (pT1b sm2) and favorable histological characteristics (G1–2, L0, V0). Strict multimodal surveillance enables timely detection of oligometastatic progression and selective lymphadenectomy, thereby avoiding esophagectomy and preserving quality of life. Further data accumulation is needed to refine patient selection criteria and optimize follow‑up protocols.

  • Predicting 90-day postoperative mortality after esophagectomy using machine learning technology: a comparative evaluation of the model with foreign analogues

    by K.I. Salimzyanov, A.B. Ryabov, V.M. Khomyakov, I.V. Kolobaev, E.I. Smolenov, N.M. Abdulkhakimov, G.S. Pogosyan, G.V. Afonin

    Objective. To compare the performance of a machine-learning-based model for predicting 90-day postoperative mortality after esophagectomy (EsoRisk) with existing prognostic scales, the ACS NSQIP and Esodata (IESG), in a single independent patient sample. Material and methods. A retrospective cohort study was conducted, including 100 patients with resectable esophageal and cardioesophageal junction cancer (Siewert I) who underwent esophagectomy at the P.Herzen Moscow Oncology Research Institute and the A.Tsyb Medical Radiological Research Center from January 2024 to November 2025. During the 90-day postoperative period, in-hospital, 30-, and 90-day mortality, as well as the incidence of postoperative complications, were assessed. The ACS NSQIP, Esodata (IESG), and EsoRisk scores were used for direct comparative analysis. Model validity was assessed using the AUC-ROC, AUPRC, Accuracy, and Brier score metrics. Results. Postoperative complications were registered in 42% of patients, Clavien–Dindo complications ≥ IIIA — in 29%. In-hospital mortality was 8%, 30-day — 2%, 90-day — 8%. In terms of discriminatory ability, EsoRisk was superior to the compared scales: AUC-ROC was 0.87 versus 0.78 for Esodata (IESG) and 0.55 for ACS NSQIP; AUPRC — 0.81 versus 0.36 and 0.36, respectively; Accuracy — 0.70 versus 0.54 and 0.46; the Brier score was minimal in the EsoRisk model and amounted to 0.10. Conclusion. The EsoRisk model, based on machine learning methods, demonstrated higher accuracy in predicting 90-day postoperative mortality after esophagectomy compared to the ACS NSQIP and Esodata (IESG) scores. These data confirm the potential of using machine learning algorithms for preoperative risk stratification in patients with esophageal cancer. The presented model can be recommended for use in institutions specializing in the surgical treatment of esophageal cancer.

  • Laparoscopic extramucosal excision of gastric gastrointestinal stromal tumor

    by A.B. Ryabov, N.M. Abdulkhakimov, D.V. Martirosyan, V.M. Khomyakov, I.V. Kolobaev, G.S. Pogosyan, A.E. Savelicheva, E.V. Gonchar, P.A. Smirnov

    Gastrointestinal stromal tumors (GISTs) are mesenchymal neoplasms arising from interstitial cells of Cajal with predominant localization in the stomach. Modern surgical management of localized gastric GISTs favors minimally invasive organ-sparing techniques ensuring total resection (R0) and reducing recovery time. This article presents laparoscopic submucosal excision of gastric antral GIST in a 63-year-old female with multiple comorbidities. A 4-cm tumor arising from muscular layer was resected without mucosal disruption. Postoperative period was uneventful, and histological examination confirmed R0 resection with low proliferative activity (Ki-67 3%). No recurrence was detected throughout 20 months. Analysis of literature data highlights the advantages of submucosal approach for small (≤5 cm) extramural gastric GISTs, including technical simplicity, lower intraoperative risks, and preserved organ function. Key selection criteria include tumor location (anterior wall/greater curvature), growth from muscular layer and no adhesions. This case supports feasibility of laparoscopic submucosal resection in carefully selected patients. Further multiple-center studies are needed to standardize this technique and evaluate long-term outcomes.

  • Open Access

    Comparative analysis of long-term outcomes of surgical and combined treatment of patients with squamous cell carcinoma of the thoracic esophagus cT2N0M0

    by K. I. Salimzyanov, A. B. Ryabov, V. M. Khomyakov, S. Yu. Dvoretsky, I. V. Kolobaev, N. M. Abdulkhakimov, B. I. Salimzyanov, С. Ю. Дворецкий

    The OBJECTIVE was to improve immediate and long-term outcomes of surgical treatment by optimizing the choice of treatment strategy for patients with squamous cell carcinoma of the thoracic esophagus cT2N0M0. METHODS AND MATERIALS. The analysis included 57 patients who underwent surgery for squamous cell carcinoma of the thoracic esophagus cT2N0M0 at the P. Hertsen Moscow Oncology Research Institute from 2005 to 2023. The upfront surgery group comprised 67 % (n=38) of the patients. Combined treatment was implemented in 19 (33 %) of the 57 patients. The accuracy of clinical staging of the tumor process was assessed, and a statistical analysis of risk factors for poor prognosis was performed. Overall and recurrence-free survival rates were evaluated using the Kaplan–Meier method. RESULTS. Subgroup statistical analysis revealed that tumors ≤4 cm in length (n=33) on endoscopy were a prognostically favorable group, regardless of the presence or absence of preoperative treatment, with all patients reaching the 5-year overall survival mark. In the group with tumors >4 cm (n=24), true pT2N0M0 was found in only 44 %, with understaging – in 56 % and overstaging – in 0 %. Analysis of long-term outcomes revealed a median overall survival of 28 months in the combined treatment group versus 26 months in the up-front surgery group (p=0.87). The 3-year overall survival was 31 % versus 40 % (p=0.977), and the 5-year overall survival was 16.6 % versus 40 % (p=0.684) respectively. CONCLUSION. Based on the study, it can be concluded that tumor length ≤4 cm is a favorable prognostic factor, and upfront surgery is preferable for such patients. In the group with tumors >4 cm, no statistically significant difference in long-term outcomes was found between the combined treatment and up-front surgery groups. However, in most cases, understaging occurs in this group, and such tumors should be interpreted as locally advanced processes, for which multimodal therapy is recommended according to current clinical guidelines.

  • Design of the multicenter cohort prospective study GASTROSTAT to analyse postoperative morbidity and mortality after elective radical surgery for gastric cancer

    by A.B. Ryabov, N.M. Abdulkhakimov, V.M. Khomyakov, P.A. Smirnov

    Gastric cancer continues to occupy the leading positions in terms of morbidity and mortality among malignant tumors. Surgical treatment remains the main method of treatment within the combined approach. However, now the level of postoperative mortality and morbidity varies greatly worldwide and in the Russian Federation due to the heterogeneity of techniques and the level of tracking of postoperative results. To develop algorithms to standardize the surgical treatment of gastric cancer and its complications, as well as to improve the quality of further studies, a multicenter cohort prospective study GASTROSTAT was conducted to analyze postoperative complications and mortality after elective radical surgery for gastric cancer. The study was initiated by the Hertsen Moscow Oncology Research Institute, a branch of the National Medical Research Radiological Centre (NMRRC) of the Ministry of Health of the Russian Federation. 45 federal centers and regional oncologic dispensaries from 30 cities of Russia and the Republic of Belarus were invited to participate in the study. All consecutive patients with primary gastric cancer (carcinoma), including esophagogastric cancer (Siewert III), who underwent elective radical surgery (gastrectomy, distal or proximal subtotal resection, etc.) via open, laparoscopic or robot-assisted access between March 18, 2024 and September 18, 2024 were included in the study, regardless of additional drug (neoadjuvant, adjuvant, perioperative, intraoperative) or radiotherapy. The purpose of this article is to present our proposed study design and its features. This design will allow us to study 90-day rates of postoperative morbidity and mortality in patients undergoing elective surgery for gastric cancer, to form a unified structure, and to develop recommendations for the prevention and reduction of postoperative general and surgical complications.

  • Short-term outcomes of the McKeown esophagectomy for thoracic esophageal cancer: a multiple-center study

    by A.B. Ryabov, O.V. Pikin, V.M. Khomyakov, I.V. Kolobaev, E.A. Toneev, N.M. Abdulkhakimov, S.V. Gamayunov, N.M. Kiselev, O.A. Alexandrov, D.D. Sobolev, et al.

    Objective. To analyze short-term outcomes of the McKeown esophagectomy in 4 cancer centers of the Russian Federation. Material and methods. The study included 175 patients who underwent open, hybrid or minimally invasive McKeown esophagectomy between 2016 and 2023 in 4 cancer centers of the Russian Federation. Traditional open esophagectomy was performed in 69 (39.4%) patients, hybrid — in 78 (44.6%), minimally invasive — in 28 (16%) patients. Results. Median time of minimally invasive surgery was 395 min [358.25; 436.25], hybrid procedure — 357.5 min [300.00; 403.75], open esophagectomy — 315 min [265.00; 390.00] (p<0.001). Mean blood loss was 175, 150 and 300 ml, respectively (p<0.001). Conversion rate for hybrid interventions was 2.5%, for minimally invasive esophagectomy — 3.5%. Mean number of resected lymph nodes was higher in minimally invasive groups (open — 19.7±7.5; hybrid — 21.3±13.1; minimally invasive esophagectomy — 21.7±12.4 p=0.007). Major postoperative complications (TMM classification) comprised 8.7% in open surgeries and 20.7% in hybrid and minimally invasive procedures (p=0.031). Pulmonary complications were more common after open esophagectomy (17.4%) compared to hybrid and minimally invasive procedures (7.5%) (p=0.041). Incidence of type 2 and 3 anastomotic leaks was 6.4% in hybrid surgery, 8.6% in open surgery and 10.7%in minimally invasive procedures (p=0.387). Postoperative in-hospital mortality was 8.6% for open esophagectomy, 5.1% for hybrid esophagectomy and 3.5% for minimally invasive procedures (p=0.049). Hospital-stay was 19 days for open esophagectomy and 14 days for hybrid and minimally invasive procedures (p=0.219). Conclusion. Minimally invasive esophagectomy for thoracic esophageal cancer significantly reduces the incidence of postoperative pulmonary complications and intraoperative blood loss, as well as increases the number of removed lymph nodes.


  • Possibilities of laparoscopic surgery in the treatment of patients with retroperitoneal tumors

    by A.B. Ryabov, V.M. Khomyakov, D.D. Sobolev, I.V. Kolobaev, N.V. Vorobyev, N.M. Abdulkhakimov, A.V. Chaika, K.I. Salimzyanov, A.A. Krasheninnikov, A.B. Utkina, et al.

    Today, radical surgical intervention is still one of the main methods of treatment for the majority of non-organ tumors in the retroperitoneal space. The rapid development of minimally invasive surgery in the last 10 years has been accompanied by an increase in the number of publications devoted to laparoscopic surgery of retroperitoneal formations. Minimally invasive surgery is a safe and technically feasible alternative to traumatic laparotomy access for localized tumors. The article presents a series of clinical observations and a review of the literature on this problem. Further accumulation of experience in performing this type of surgery and follow-up of these patients will make it possible to evaluate the long-term results and form criteria for selecting patients for minimally invasive treatment.

  • Hiatal hernia after esophagectomy

    by A.B. Ryabov, O.V. Pikin, V.M. Khomyakov, I.V. Kolobaev, N.M. Abdulkhakimov

    Objective. To analyze the causes and surgical treatment of hiatal hernia after esophagectomy, technical features of surgery and methods of prevention. Material and methods. We retrospectively analyzed the incidence of postoperative hiatal hernias after esophagectomy in patients with esophageal cancer between 2018 and 2023. Structure of hernias, surgical options and postoperative results were assessed. Results. We analyzed 161 patients after Ivor Lewis (n=101) and McKeown (n=60) esophagectomies (open surge surgeries — 43.5%, thoraco- and laparoscopic procedures — 23%, hybrid procedures — 33.5%). The incidence of postoperative hiatal hernia was 3.7%. Hernia occurred within 1—15 months. There were 5 men and 1 woman (mean age 65 years). In all cases, partial or complete dissection of the left diaphragmatic crura was performed. The incidence of hernia after minimally invasive surgery was 4.4%, after open surgery — 2.9%. Two (33.3%) patients underwent urgent surgery for ileus within 2 months after primary esophageal surgery. Three (50%) patients underwent elective surgery. One (16.6%) patient is currently followed-up. The complication was asymptomatic in 2 (33.3%) patients. One (16.6%) patient died after emergency surgery in a COVID hospital due to strangulated hernia and progressive respiratory failure. Mean follow-up period was 16 months. No recurrent hernias were diagnosed. Conclusion. Hiatal hernias occur 2 times more often after minimally invasive esophagectomies. Active surgical strategy is necessary for symptomatic hernias due to high risk of strangulation and emergency interventions. The incidence of this complication is lower without wide diaphragmotomy, transection of the left diaphragmatic crus and high abdominal pressure during laparoscopic stage.